Clinical Trial Update: Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of regorafenib in recurrent ovarian, primary peritoneal, and fallopian tube cancer was terminated with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: University of Utah | Conditions: Ovarian Cancer, Primary Peritoneal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-12-02